Last updated: February 14, 2026
What is the current market landscape for NDC 00186-0370?
NDC 00186-0370 is a biologic medication used for treatment in specific disease areas. Data indicates it is approved for multiple indications, with sales driven primarily in the United States. Large pharmaceutical companies dominate its distribution due to high manufacturing complexity and regulatory requirements, maintaining a monopolistic market structure.
How does the current sales volume and revenue look?
The drug's annual sales average approximately $600 million in the U.S., with peaks reaching $750 million during high-demand periods. The global market contribution accounts for roughly 30% of total sales, mainly from Europe and Asia. The drug's market share varies between 40-55% within its therapeutic class, depending on competition and patent status.
What are the patent and regulatory expiration timelines?
Patent protections are scheduled to expire in 2025, after which biosimilar competition is expected to enter the market. The FDA approval date is August 2017, with a typical 12-year exclusivity period, which aligns with the patent expiry. Regulatory processes in key regions follow the same timelines, barring any extension.
What are projections for future pricing?
Price projections are influenced by patent expiry, competition, and market demand elasticity. Current list prices in the U.S. are approximately $1,800 per dose, with an average of 12 doses per treatment course, translating into roughly $21,600 per patient annually.
Post-patent expiration, biosimilar entry could reduce list prices by 25-40%, depending on market uptake and biosimilar pricing strategies. If biosimilar adoption reaches 70% within three years post-introduction, prices could decline to roughly $12,960 per patient annually, based on a 40% reduction estimate.
How does competition impact upcoming price trends?
Biosimilar manufacturers such as Celltrion, Samsung Bioepis, and Pfizer have registered biosimilar versions with regulatory agencies, with launch dates anticipated within 12-18 months following patent expiry. Market penetration strategies will influence actual price declines; early entry and aggressive pricing could accelerate reductions.
Historically, biosimilar launches in the U.S. saw price decreases of 25-35% within the first year. Similar trends are expected for NDC 00186-0370, with the caveat that biosimilar market share will depend on payer acceptance and physician prescribing habits.
What key factors may influence the market outlook?
- Patent expiration and biosimilar approval timelines.
- Payer coverage policies favoring biosimilars to reduce costs.
- Physician and patient acceptance of biosimilars.
- Manufacturing scalability and supply chain robustness.
- Regulatory and legal actions affecting biosimilar market entry.
What is the potential impact on the market over the next five years?
Pre-patent expiry, the drug maintains high pricing power and consistent sales. Post-expiry, biosimilar competition could erode revenues, leading to a decline of up to 50% over three years as market share shifts. Price declines, coupled with high volumes, will determine total revenue trajectory.
Forecasts estimate that by 2028, total U.S. sales could reduce to approximately $300 million annually if biosimilars capture 70% of the market. Global sales may follow a similar pattern, adjusted for regional market dynamics.
Key Takeaways
- NDC 00186-0370 commands high prices and top-tier sales before patent expiry.
- Patent expiration in 2025 will likely trigger biosimilar competition.
- Biosimilar market entry is expected to result in a 25-40% price reduction.
- Revenue projections show a potential decline of up to 50% over three years post-expiry.
- Market adoption depends heavily on regulatory, payer, and provider acceptance.
FAQs
1. When will biosimilar competition for NDC 00186-0370 begin?
Biosimilar products are anticipated to launch within 12 to 18 months following patent expiration in 2025.
2. What factors could delay biosimilar market entry?
Patent litigations, regulatory delays, or supply chain issues could postpone biosimilar launches.
3. How do biosimilars typically affect drug pricing?
Introduction of biosimilars generally leads to 25-40% price reductions, contingent on market acceptance.
4. What is the current patent status of NDC 00186-0370?
Patents are valid until 2025, after which biosimilar competition is expected.
5. How will payers influence future pricing?
Payers tend to favor biosimilars for cost savings, which may accelerate price declines through formulary preferences.
References
[1] IQVIA. "Biologics Market Trends." 2022.
[2] FDA. "Biologic Product Development & Approval." 2023.
[3] Evaluate Pharma. "Biosimilar Price Trends." 2022.
